locoregional therapy

Nikolas Naleid: Excited to share our systematic review on pembrolizumab safety in GI cancers

Nikolas Naleid, Internal Medicine resident at Case Western Reserve/UH Cleveland Medical Center, shared a recent article by him and colleagues on X:

“Excited to share our systematic review on pembrolizumab safety in GI cancers was published in Biomedicines MDPI.

Overview:

  •  25 studies, 3101 patients (median age 62, 30.2% F).
  • Cancer types: CRC (12%), EG (46%), HCC (24%), other GI (18%)

Decreased irAE rates:

  • Discontinuation: 6.8%
  • Grade ≥3: hepatitis 3.6%, pneumonitis 0.8%, colitis 0.7%
  • Death: 0.9%”

“Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials“

Authors: Nikolas Naleid, Amit Mahipal and Sakti Chakrabarti

Nikolas Naleid

More posts featuring Nikolas Naleid.

Amit Mahipal Biomedicines MDPI cancer clinical trials gastrointestinal cancers hepatitis Nikolas Naleid OncoDaily Oncology pembrolizumab Sakti Chakrabarti